Free Trial

Aclarion (ACON) Competitors

Aclarion logo
$7.50 -0.18 (-2.34%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$7.50 0.00 (-0.07%)
As of 07/3/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACON vs. ENZ, BRTX, MGRX, SSY, BGLC, VSEE, ATIP, DHAC, OTRK, and NIVF

Should you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Enzo Biochem (ENZ), Biorestorative Therapies (BRTX), Mangoceuticals (MGRX), SunLink Health Systems (SSY), BioNexus Gene Lab (BGLC), VSee Health (VSEE), ATI Physical Therapy (ATIP), Digital Health Acquisition (DHAC), Ontrak (OTRK), and NewGenIvf Group (NIVF). These companies are all part of the "healthcare" industry.

Aclarion vs. Its Competitors

Enzo Biochem (NYSE:ENZ) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Aclarion had 1 more articles in the media than Enzo Biochem. MarketBeat recorded 1 mentions for Aclarion and 0 mentions for Enzo Biochem. Aclarion's average media sentiment score of 0.59 beat Enzo Biochem's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company Overall Sentiment
Enzo Biochem Neutral
Aclarion Positive

Aclarion has a consensus target price of $11,758.50, indicating a potential upside of 156,680.00%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Enzo Biochem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enzo Biochem
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aclarion
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Enzo Biochem has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

Enzo Biochem has a net margin of -75.34% compared to Aclarion's net margin of -12,227.10%. Enzo Biochem's return on equity of -7.96% beat Aclarion's return on equity.

Company Net Margins Return on Equity Return on Assets
Enzo Biochem-75.34% -7.96% -5.49%
Aclarion -12,227.10%-126.89%-106.61%

Aclarion has lower revenue, but higher earnings than Enzo Biochem.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enzo Biochem$29.09M0.59-$26.08MN/AN/A
Aclarion$50K87.00-$6.99MN/AN/A

36.9% of Enzo Biochem shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 11.4% of Enzo Biochem shares are owned by company insiders. Comparatively, 0.8% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Aclarion beats Enzo Biochem on 7 of the 13 factors compared between the two stocks.

Get Aclarion News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACON vs. The Competition

MetricAclarionMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$4.35M$7.31B$5.53B$9.02B
Dividend YieldN/A2.78%5.22%3.99%
P/E RatioN/A27.9427.7020.25
Price / Sales87.0032.39419.56119.26
Price / CashN/A20.3926.2128.59
Price / Book0.156.698.035.65
Net Income-$6.99M$233.06M$3.18B$249.15M
7 Day Performance-0.40%2.51%2.88%2.91%
1 Month Performance9.17%1.79%1.67%4.11%
1 Year Performance-99.71%37.40%34.39%20.98%

Aclarion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACON
Aclarion
2.2648 of 5 stars
$7.50
-2.3%
$11,758.50
+156,680.0%
-99.7%$4.35M$50K0.007
ENZ
Enzo Biochem
N/A$0.33
-14.8%
N/A-69.3%$17.03M$29.09M0.00520Gap Down
High Trading Volume
BRTX
Biorestorative Therapies
2.7439 of 5 stars
$1.67
+3.5%
$18.00
+980.7%
-15.3%$12.49M$400K-1.137
MGRX
Mangoceuticals
0.8373 of 5 stars
$1.52
-12.1%
N/A-97.8%$7.86M$620K-0.333Positive News
Gap Down
SSY
SunLink Health Systems
N/A$0.88
+0.6%
N/A+10.7%$6.20M$31.09M6.291,376
BGLC
BioNexus Gene Lab
0.4104 of 5 stars
$3.07
+10.8%
N/A+36.0%$5.53M$9.51M0.0030Gap Down
VSEE
VSee Health
1.1861 of 5 stars
$1.16
+5.5%
$5.00
+331.0%
N/A$4.18MN/A0.00N/AGap Up
ATIP
ATI Physical Therapy
0.1948 of 5 stars
$0.90
+4.7%
N/A-80.2%$3.97M$741.86M-0.055,600Gap Down
DHAC
Digital Health Acquisition
N/A$1.10
-3.5%
N/A-86.8%$3.96MN/A0.002,021Gap Down
OTRK
Ontrak
2.8838 of 5 stars
$0.50
-9.8%
$45.00
+8,916.2%
-84.1%$2.11M$10.85M-0.03250High Trading Volume
NIVF
NewGenIvf Group
N/A$1.04
+1.0%
N/A-99.5%$543K$5.43M0.00N/AGap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ACON) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners